Navigation Links
Neogen reports 30% increase in quarterly net income
Date:12/20/2012

LANSING, Mich., Dec. 20, 2012 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that its net income for the second quarter of FY 2013, which ended Nov. 30, increased 30% to $6,793,000, from the previous year's second quarter net income of $5,237,000. For the quarter, earnings per share was $0.28, compared to $0.22 a year ago.

Second quarter revenues increased 13% to $50,737,000, a record quarter for the 30-year-old company, compared to the prior year's $44,891,000. Year to date, FY 2013 revenues increased 11% to $100,467,000 from FY 2012's $90,588,000. Year-to-date net income increased 20% to $13,507,000, or $0.56 per share, from $11,241,000 in FY 2012, or $0.47 per share.

"Our strong second quarter was led by significant initial sales of recently developed product lines, and an acquisition that was immediately accretive to both our top and bottom lines," said James Herbert, Neogen's chief executive officer and chairman. "We launched our innovative Reveal Q+ tests for mycotoxins in time to respond to significant mycotoxin outbreaks, and our new Reveal 3-D tests for food allergens specifically address expanding global regulatory testing requirements. Sales of Uniprim, the popular antibiotic we acquired in early October, were aided by our stronger sales and marketing organization."

The second quarter was the 75th consecutive profitable quarter from operations for the company, and the 83rd quarter of the past 88 quarters that Neogen reported revenue increases as compared with the previous year — including the last 31 consecutive quarters.

"A significant portion of our second quarter growth was due to increases in same-store sales of key products, including natural toxin and food allergen diagnostics on our Food Safety side, and small animal supplements and rodenticides on our Animal Safety side," said Lon Bohannon, Neogen's presi
'/>"/>

SOURCE Neogen Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neogen Corporation Announces 1st Quarter Results Conference Call
2. Neogen reports year end results
3. Neogen Corporation Announces Year-End Results Conference Call
4. Neogen acquires Igenity from Merial
5. Neogen launches the fastest molecular pathogen test
6. Neogen Launches Fully Quantitative Lateral Flow Test for DON
7. Neogen Reports Second Quarter Results
8. Neogen Corporation Announces 2nd Quarter Results Conference Call
9. Murray Test Prep Reports In-home Tutoring is the New Trend in Education
10. Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
11. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Germany will present itself as one of the,world,s ... BIO,International Convention. Under the "Breakthroughs in Regenerative Medicines,in ... into the,latest research results in the area of ... the regulatory framework conditions will be,introduced in a ...
... Corporation (Nasdaq: MATK ) announced that it intends ... 2009 on June 3, 2009, at approximately 4:00 p.m. Eastern ... Martek will conduct a conference call to discuss these results ... call live via webcast by visiting Martek,s web site at ...
... North Carolina And ChinaRESEARCH TRIANGLE PARK, N.C., May ... Health Sciences has signed an agreement with China ... Institute for International Drug Development. Building on strengths ... development, and education, the Institute will help to ...
Cached Biology Technology:BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2The Hamner Institutes Announce Partnership With China Medical City 2The Hamner Institutes Announce Partnership With China Medical City 3
(Date:4/17/2014)... Researchers in France have hit on a novel ... receive the correct and most effective treatment possible., ... the western and developing world. If left untreated, ... to renal failure and other complications. In many ... problem. Clearly a more effective pathological approach to ...
(Date:4/17/2014)... Indiana University researchers have detected new early-warning signs of ... discovery could have far-reaching implications for the diagnosis and ... over 25 million Americans. , "We had not expected ... such early stages," said Ann Elsner, professor and associate ... author of the study. "We set out to study ...
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Some immune cells defend only 1 organ 2
... Barbara, CA The Bren School-based authors of a study ... have observed toxicity to marine organisms resulting from exposure to ... toxic under similar conditions. Lead author and assistant research ... both Bren School professors and lead scientists at the ...
... at the University of California, Riverside discovered a tiny fairyfly wasp ... United States until then. Nearly exactly a year later, he ... is well established in the country. Called Gonatocerus ater ... North America from Europe. It lays its eggs inside the ...
... New Rochelle, NY, January 24, 2012The time for commercial development ... and curable with gene therapy deserve access to the technology, ... Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy ... . Human Gene Therapy and Human Gene ...
Cached Biology News:Nano form of titanium dioxide can be toxic to marine organisms 2Wasp found in upstate New York shows up in Southern California 2Gene therapy is a 'disruptive science' ready for commercial development 2